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Dementia is a progressive decline in the ability to remember,
learn, understand, and communicate. Alzheimer’s disease
(AD) represents the most common form of dementia in the
elderly, aﬀecting about 28 million individuals worldwide.
Current treatments for AD and other dementias are sorely
limited, falling short of preventing or signiﬁcantly slowing
disease progression. Worldwide, the number of people
aﬄictedbyADisexpectedtoexceed100millionby2050,asa
resultoftheincreasedlife-spanexpectancyinbothdeveloped
and developing countries [1]. Compelling epidemiological
observations suggest that human nutrition and lifestyle
factors can modify the risk of late onset dementia. For
example, overweight in midlife has been associated with an
increased risk for dementia in late life [2], and frequent
consumption of fruits and vegetables, ﬁsh, and omega-3 rich
oils is associated with decreased AD risk. Dietary patterns
such as the “Mediterranean diet,” characterized by high
intake of vegetables, legumes, fruits, cereals, and unsaturated
fatty acids have also been associated with decreased risk of
developing mild cognitive impairment (MCI) and of MCI
conversion to AD [3]. There is also evidence that higher
intake and status of speciﬁc nutrients such as vitamin E,
vitamin B12, and folate may be protective against cognitive
decline and aging [4]. Similarly, intake of antioxidants, such
as vitamin E and C, and fatty ﬁsh have been found to be
protective against vascular dementia (VaD) risk, whilst fried
ﬁsh intake and elevated homocysteine are associated with
increased risk [5].
Despite this, evidence for the cognitive beneﬁt of nutri-
tional and lifestyle interventions in age-associated cognitive
impairment and dementia remains equivocal, and a clear
elucidation of mechanisms remains elusive. Although some
good evidence is available for the beneﬁcial eﬀect of nutri-
tional interventions on neurocognitive outcomes [6], most
large scale nutritional randomized clinical trials to date have
failed to clearly demonstrate eﬃcacy in mitigating cognitive
impairment and dementia (as well as other chronic condi-
tions). This gap between the epidemiological evidence and
interventional trials has prompted a critical re-evaluation
of conceptual and practical limitations of clinical trials of
nutritional interventions and the need for better trial design
[7–9], while at the same time redoubling eﬀorts in funda-
mental research to clarify the underlying pathophysiological
mechanisms of the indicated interventions.
This special issue presents timely review articles and
research papers covering several aspects of nutrition in de-
mentia providing a forum for the critical evaluation and
delineation of new approaches and opportunities for nutri-
tional and lifestyle interventions. Three papers in this issue
address the role of obesity in dementia. R. Businaro et al.
reviewed the molecular mechanisms linking obesity to AD
risk, focusing on the correlation between the onset and
progression of the disease and the stress-induced changes
in lifestyle, leading to overnutrition and reduced physical
activity,endingwithmetabolicsyndromeandobesity.Partic-
ularly, the authors reviewed the factors leading to alterations
of energy metabolism in favour of visceral fat accumulation
and the subsequent promotion of insulin resistance and
chronic inﬂammation, both critical factors for AD initiation
and progression. They also discussed strategies to reduce
abdominal fat deposits and their beneﬁcial role on cognitive
decline in a comprehensive and updated review article. It2 Current Gerontology and Geriatrics Research
is clear from this review that hyperinsulinemia is one of
the most frequent endocrine features in overweight people
leading to insulin desensitization and represents a risk factor
for cognitive decline. This point was discussed also by L.
Moll and M. Schubert that reviewed the literature dealing
with the role of insulin and insulin-like growth factor-1 in
the pathogenesis of obesity-associated dementia, with focus
on the possible contribution of forkhead-box transcription
factors (FoxO). FoxO are mediators of insulin and insulin-
like growth factor-1 involved in several processes including
neuronal proliferation, diﬀerentiation, stress response, and
β-amyloid detoxiﬁcation. In this original review article,
the authors discuss the few studies performed so far in
animal models to investigate the possible contribution of
FoxO-mediated transcription to AD pathology. Studies in
C. elegans are in conﬂict with those performed in mice that
suggest that FoxO-mediated transcription does not protect
against but rather increase amyloid pathology. However, the
small number of published papers limits our understanding
of the role of this pathway in dementia, and additional
research is required to fully address this interesting topic.
It is also noteworthy that FoxO-mediated transcription is
not the only mediator of the insulin and insulin-like growth
factor-1 cascade, and that several factors might therefore be
involved in the pathogenesis of dementia. As an example,
insulinresistanceandinﬂammation,observedinpeoplewith
an excess of visceral adiposity, are also believed to contribute
to metabolic deterioration of skeletal muscle, manifesting
clinically as sarcopenia. M. E. Levine and E. M. Crimmins
investigated the inﬂuence of insulin resistance and inﬂam-
mation on the association between body composition and
cognitive performance in older adults. The study included
1127 adults from the US National Health and Nutrition
ExaminationSurvey(NHANES1999–2002)andshowedthat
body composition does not predict cognitive functioning
in adults aged 60–69 years, but, for adults aged 70 years
and over, sarcopenia and obesity, either independently or
concurrently, were associated with worse cognitive func-
tioning (WAIS III, Digit Symbol substitution performance)
relative to nonsarcopenic nonobese older adults. Cognitive
functioning was lowest among the sarcopenic obese group,
and sarcopenic obese people also showed the highest levels
of inﬂammation. Moreover, insulin resistance accounted for
asigniﬁcantproportionoftherelationshipbetweencognitive
performance and obesity, with or without sarcopenia. This is
a novel, interesting, and important study on the association
between sarcopenic obesity, insulin resistance, and cognitive
functioning strengthened by the large sample size and
suggesting that individuals who are sarcopenic obese have
a lower cognitive ability than other subjects, and that this
association might be partially explained by insulin resistance
and inﬂammation. Aging seems also to be an important
factor to be considered in order to see a signiﬁcant eﬀect.
The study has, however, several limitations that the authors
have acknowledged, including the lack of longitudinal data
to evaluate whether insulin resistance precedes frailty and
cognitive decline, the use of a single measure of cognitive
functioningtostudycognitiveperformance,andthefactthat
insulin resistance and inﬂammation were measured only one
point in time. However, it provides preliminary interesting
data for the design of longitudinal studies to better address
this issue. Collectively, these three papers provide new
insight into the role that obesity, metabolic syndrome and
sarcopenia might play in dementia, by focusing on possible
biological mechanisms or by providing novel and interesting
preliminary data on humans.
G. L. Bowman et al. analysed 36 subjects with mild-
to-moderate AD investigating the correlation between dys-
lipidemia and blood-brain barrier (BBB) impairment. The
CSF-to-serum ratio of albumin (CSF Albumin Index) ≥9
was considered as BBB impairment. The study revealed
that dyslipidemia was frequent in AD subjects with BBB
impairment. Furthermore, patients with BBB dysfunction
showed signiﬁcantly higher mean plasma triglyceride and
lower HDL cholesterol levels with respect to those without
BBB dysfunction. Overall, plasma triglycerides explained
22% of the variance in BBB integrity and remained signif-
icant after correcting for age, gender, APOE-ε4 genotype,
blood pressure, and statin use. This research paper adds
to the growing literature on BBB dysfunction in AD by
suggesting that dyslipidemia may have a detrimental role
in maintaining BBB integrity in mild-to-moderate AD. The
limitofthisstudyistheverysmallsamplesize,andadditional
studies are required to demonstrate a causal link between
dyslipidemia and BBB impairment. However, if replicated
in other populations, these ﬁndings might gain clinical
signiﬁcance because dyslipidemia is treatable.
Another important issue is that of the diﬃculties asso-
ciated with maintaining adequate nutrition in individuals
withdementia.Nutritionandappetitedeclinewithage,often
accompanied by weight loss. This is particularly critical in
advanced dementia where progressive feeding problems can
become so severe that physicians and families must decide
whether artiﬁcial nutrition and hydration is required. This
importantissueisdiscussedinthereviewarticlebyG.A.Pivi
and colleagues.
B vitamins and methyl-group homeostasis have received
considerable attention in recent years, providing a basis for
understanding the complex interplay between nutrition and
epigenetic modiﬁcations of disease-related genes, including
those that are involved in aging and in Alzheimer’s disease.
For example, experimental modiﬁcation of methyl-group
homeostasis through dietary deﬁciency and supplementa-
tion of choline and folate has been shown to exert pro-
found eﬀects on brain development, function, and aging
[10–12], including epigenetic modiﬁcation and/or aberrant
expression of key AD genes [13]. In light of this attention,
it has been turned to the potential impact of food folic acid
fortiﬁcation and nutritional status in human metabolic pro-
gramming [14, 15].
Nicotinamide methylation is another potentially impor-
tant mechanism that is theoretically susceptible to altered
methylationpotential,butonethatisfarlessstudied.Dietary
impairment of this pathway might contribute to disturbed
energy metabolism and cholinergic neurotransmission in
dementia. A. C. Williams and colleagues draw attention to
the role that this pathway may play in age-related cognitive
impairment, by taking pellagra, as an example, a severeCurrent Gerontology and Geriatrics Research 3
vitamin deﬁciency disease most commonly caused by a
chronic lack of niacin (vitamin B3) in the diet, and leading
to dementia, dermatitis, diarrhoea, and death. Niacin status
is not well studied in relation to dementia risk, either alone
orinrelationtomethyl-groupmetabolismalthoughthereare
experimental animal data showing beneﬁts of supplementa-
tion [16]. More research in this area is warranted.
Overall, it is becoming clear that dietary factors play a
fundamental role in brain health throughout the lifespan.
Improving nutrition and dietary habits during early life and
adulthood might therefore be an eﬀective strategy to coun-
teract age-related diseases.
We hope that this special issue will contribute to our
understanding of the complex interplay between nutrition
and dementia and thereby advance our collective eﬀorts to
prevent, delay, and manage this debilitating disease.
We are extremely grateful to all the authors for their con-
tributionsthatmadepossibletocoverseveraltimelytopicsin
this special issue.
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